Arizona State Retirement System Has $144,000 Stake in Kura Oncology, Inc. (NASDAQ:KURA)

Arizona State Retirement System boosted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURAFree Report) by 9.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,823 shares of the company’s stock after buying an additional 1,406 shares during the quarter. Arizona State Retirement System’s holdings in Kura Oncology were worth $144,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Franklin Resources Inc. lifted its holdings in Kura Oncology by 2.8% during the 2nd quarter. Franklin Resources Inc. now owns 1,224,497 shares of the company’s stock worth $12,955,000 after buying an additional 32,821 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Kura Oncology by 10.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 261,744 shares of the company’s stock valued at $2,387,000 after purchasing an additional 25,677 shares during the period. Suvretta Capital Management LLC lifted its stake in shares of Kura Oncology by 6.9% in the 2nd quarter. Suvretta Capital Management LLC now owns 7,028,442 shares of the company’s stock valued at $74,361,000 after purchasing an additional 455,107 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Kura Oncology by 4.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 50,700 shares of the company’s stock valued at $462,000 after purchasing an additional 2,013 shares during the period. Finally, Prosight Management LP acquired a new position in shares of Kura Oncology in the 2nd quarter valued at about $14,213,000.

Analyst Upgrades and Downgrades

KURA has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Friday, December 8th. StockNews.com raised Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, February 1st. Mizuho assumed coverage on Kura Oncology in a research note on Friday, December 22nd. They set a “buy” rating and a $26.00 price target on the stock. Wedbush dropped their price target on Kura Oncology from $40.00 to $37.00 and set an “outperform” rating on the stock in a research note on Friday, November 3rd. Finally, JMP Securities upped their price target on Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.28.

Read Our Latest Research Report on Kura Oncology

Kura Oncology Stock Performance

Shares of KURA opened at $19.97 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.71 and a current ratio of 16.71. The stock has a 50 day moving average price of $15.21 and a two-hundred day moving average price of $11.47. The firm has a market capitalization of $1.48 billion, a P/E ratio of -9.89 and a beta of 0.85. Kura Oncology, Inc. has a 52 week low of $7.41 and a 52 week high of $22.92.

Insiders Place Their Bets

In other Kura Oncology news, COO Kathleen Ford sold 1,496 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at approximately $384,515.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Kura Oncology news, COO Kathleen Ford sold 1,496 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at approximately $384,515.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $20.23, for a total value of $1,841,981.96. Following the sale, the chief executive officer now directly owns 559 shares of the company’s stock, valued at $11,308.57. The disclosure for this sale can be found here. In the last ninety days, insiders sold 96,919 shares of company stock valued at $1,946,415. Corporate insiders own 5.40% of the company’s stock.

Kura Oncology Company Profile

(Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.

See Also

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURAFree Report).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.